Pharmacometrics and systems pharmacology for metabolic bone diseases. Issue 6 (28th February 2019)

• Record Type: Journal Article
• Authors: Riggs, Matthew M.; Cremers, Serge
• Is Part Of: British journal of clinical pharmacology. Volume 85:Issue 6(2019)
• Page Start: 1136
• Page End: 1146
• Publication Date: 2019-02-28
• Subjects: drug development -- modelling and simulation -- pharmacokinetic‐pharmacodynamic -- pharmacometrics -- systemic pharmacology; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13881
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Mathematical modelling and simulation (M&S) of drug concentrations, pharmacologic effects and the (patho)physiologic systems within which they interact can be powerful tools for the preclinical, translational and clinical development of drugs. Indeed, the Prescription Drug User Fee Act (PDUFA VI), incorporated as part of the FDA Reauthorization Act of 2017 (FDARA), highlights the goal of advancing model‐informed drug development (MIDD). MIDD can benefit development across many drug classes, including for metabolic bone diseases such as osteoporosis, cancer‐related and numerous rare metabolic bone diseases; conditions characterized by significant morbidity and mortality. A drought looms in terms of the availability of new drugs to better treat these devastating diseases. This review provides an overview of several M&S approaches ranging from simple pharmacokinetic to integrated pharmacometric and systems pharmacology modelling. Examples are included to illustrate the use of these approaches during the development of several drugs for metabolic bone diseases such as bisphosphonates, denosumab, teriparatide and sclerostin inhibitors (romosozumab and blosozumab).